Higher Risk of Dying After Vaccination with AstraZeneca Than of Dying after Getting Covid


Following the suspension of the AstraZeneca vaccine on 11 March, the Norwegian Institute of Public Health states:

Norway decided to discontinue the use of the AstraZeneca vaccine in March, ” said Geir Bukholm, director of the Division of Infection Control and Environmental Health at the Norwegian Institute of Public Health.

“Based on this knowledge, we come up with a recommendation to remove the AstraZeneca vaccine from the Norwegian Coronavirus Immunization Program,” said Bukholm.

Bukholm points out that this was not an easy recommendation to make. It has a direct consequence for the time when risk groups can receive a coronavirus vaccine, with subsequent protection, while having an impact on when it will be possible to lift infection control measures.

Norway has dramatically reduced the risk of death from covid. And, as most older people have either been vaccinated or will soon be vaccinated, this means that the continued use of the vaccine would take place in the under-65 age group.

The calculations were based on Norwegian data in which the risk of dying from COVID-19 in different age groups is compared with the risk of dying from severe blood clots seen after vaccination with AstraZeneca.
Because there are few people dying from COVID-19 in Norway, the risk of dying from vaccination with the AstraZeneca vaccine would be higher than the risk of dying from the disease, especially for younger people,” says Bukholm.
In addition, there is reason to assume that there is skepticism on the part of the population about the use of the AstraZeneca vaccine in Norway and it is not certain how many people would now accept an offer of this vaccine, once suspended.
People who have received the first dose of AstraZeneca will be given another vaccine for their second dose. “We will come back with more specific information about when and how people who received the first dose will receive the second dose. One dose provides good protection against COVID-19 for at least 12 weeks,” says Bukholm.
The European Medicines Agency (EMA) also announced on April 9 that it has begun to investigate whether there is an association between the vaccine and several reported cases of severe blood clots among vaccinated people.
Janssen announces a break in deliveries to Europe after the US Food and Drug Administration (FDA) and the Centers for Disease Control and Prevention (CDC) recommended a temporary halt to the use of the Janssen vaccine, following reports of several cases of blood clots. severe blood after vaccination in the US.
“The use of the Janssen vaccine in Norway has been suspended until more information is available from ongoing investigations,” Bukholm said.
The Norwegian Institute of Public Health estimates that removing the AstraZeneca vaccine from the immunization program would delay it by about two weeks. At the same time, not using the Janssen vaccine would delay the immunization program by up to 7 weeks for some age groups.

Chris Black
Chris Black
"Journalism is printing what someone else does not want printed: everything else is public relations."